收藏切换
Cost-effectiveness analysis of two kinds of fixed-ratio combination of basal insulin and GLP-1RA for treatment of patients with type 2 diabetes mellitus in China
收藏切换
PDF
Ning GAO1, Bing FENG1, Sheng-nan GAO2, Yu-xi ZHANG1, Ran-ran ZHANG1, Guo-qiang LIU1
Chinese Journal of New Drugs and Clinical Remedies | 2025, 44(4) : 307 - 314
Less
收藏切换
Chinese Journal of New Drugs and Clinical Remedies | 2025, 44(4): 307-314
Original Article
Cost-effectiveness analysis of two kinds of fixed-ratio combination of basal insulin and GLP-1RA for treatment of patients with type 2 diabetes mellitus in China
Full
Ning GAO1, Bing FENG1, Sheng-nan GAO2, Yu-xi ZHANG1, Ran-ran ZHANG1, Guo-qiang LIU1
Affiliations
  • 1. Department of Clinical Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang HEBEI 050051, China
  • 2. Hebei Society for Integrated Drug and Health Technology Assessment, Shijiazhuang HEBEI 050051, China
Published: 2025-04-25 doi: 10.14109/j.cnki.xyylc.2025.04.11
Outline
收藏切换

AIM To evaluate the cost-effectiveness of insulin degludec-liraglutide(iDegLira) versus insulin glargine-lixisenatide (iGlarLixi) in Chinese adult type 2 diabetes mellitus (T2DM) patients. METHODS From the perspective of China’s health system, a Markov model was developed. Quality-adjusted life years (QALY) were used as the health output indicator, and three times 2023 gross domestic product (GDP) per capita of China was used as the willingness-to-pay (WTP) threshold. The model simulates the health output and medical costs over 30 years, evaluates the economics of the two treatment options using the incremental cost-effectiveness ratio (ICER) as an evaluation metric, and performs sensitivity and contextual analyses to test the uncertainty of the results. RESULTS Compared with the iGlarLixi scheme,iDegLira scheme had an incremental cost of 46 142.61 yuan, an incremental utility of 0.014 QALY. The ICER was 3 258 162.70 yuan·QALY-1, which was much larger than the WTP threshold (268 074 yuan·QALY-1) and was not cost-effectiveness. The results of the sensitivity analysis show that the underlying analysis was relatively robust. The results of the contextual analysis showed that the cost-effectiveness of the two schemes was comparable when the price was reduced by 31% at the current WTP threshold. CONCLUSION For Chinese adult T2DM patients with poor glycemic control despite receiving basal insulin in combination with oral hypoglycemic agents, iDegLira scheme has a lower probability of being economical at current prices compared with the iGlarLixi scheme.

insulin degludec-liraglutide  /  insulin glargine-lixisenatide  /  type 2 diabetes mellitus  /  Markov model  /  cost-effectiveness analysis
Ning GAO, Bing FENG, Sheng-nan GAO, Yu-xi ZHANG, Ran-ran ZHANG, Guo-qiang LIU. Cost-effectiveness analysis of two kinds of fixed-ratio combination of basal insulin and GLP-1RA for treatment of patients with type 2 diabetes mellitus in China[J]. Chinese Journal of New Drugs and Clinical Remedies, 2025 , 44 (4) : 307 -314 . DOI: 10.14109/j.cnki.xyylc.2025.04.11
Year 2025 volume 44 Issue 4
PDF
166
73
Cite this Article
BibTeX
Article Info
doi: 10.14109/j.cnki.xyylc.2025.04.11
  • Receive Date:2024-06-20
  • Online Date:2025-12-15
  • Published:2025-04-25
Article Data
Affiliations
History
  • Received:2024-06-20
  • Accepted:2024-12-14
Funding
Affiliations
    1. Department of Clinical Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang HEBEI 050051, China
    2. Hebei Society for Integrated Drug and Health Technology Assessment, Shijiazhuang HEBEI 050051, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/10.14109/j.cnki.xyylc.2025.04.11
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT